A DEA judge cancelled a hearing to consider a proposal to reclassify marijuana amid allegations that officials at the agency ...

AdvisorShares Pure US Cannabis, a popular exchange-traded fund tracking marijuana stocks, slid 3.6% to $3.44 on Thursday, hovering near an all-time low hit the day before. Shares of the biggest ...

DEA Administrative Law Judge John Mulrooney has canceled the first hearings on the proposal to reschedule cannabis to a Schedule III drug after ...

A Drug Enforcement Administration (DEA) judge is condemning the agency over its “unprecedented and astonishing” defiance of a ...

The Drug Enforcement Administration (DEA) is asking an agency judge to reject a request to have it removed from upcoming ...

DEA's refusal to comply with direct orders is “unprecedented and astonishing," says the judge overseeing the marijuana ...

The cannabis industry faces significant challenges. While the proposed rescheduling of cannabis could provide some tax and ...

In 2025, cannabis faces major changes with federal reclassification, easing regulations, increasing research, and opening ...

DEA judge orders agency to respond to allegations of opposing marijuana rescheduling and improper communication with opponents. Cannabis stocks declined in 2024 due to concerns about DEA review.

Company views delay as imperative administrative step and symbolic win for industry against conflicted DEA –– Company condemns agency ...

Shares of cannabis stocks slumped after a company set to testify in the Drug Enforcement Administration's rescheduling hearings accused the agency of obstructing the rulemaking process.

Alexander Malyshev and Sarah Ganley of Carter Ledyard & Milburn LLP discuss what the cannabis sector can expect as 2025 ...